BACKGROUND: Staphylococcus aureus is the most common cause of endovascular infections. The staphylococcal accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant S. aureus (MRSA) persistence in such infections via its influence on biofilm formation. METHODS: Two healthcare-associated MRSA isolates from patients with persistent bacteremia and 2 prototypical community-acquired MRSA strains, as well as their respective isogenic sarA mutants, were studied for in vitro biofilm formation, fibronectin-binding capacity, autolysis, and protease and nuclease activities. These assays were done in the presence or absence of sub-minimum inhibitory concentrations (MICs) of vancomycin. In addition, these strain pairs were compared for intrinsic virulence and responses to vancomycin therapy in experimental infective endocarditis, a prototypical biofilm model. RESULTS: All sarA mutants displayed significantly reduced biofilm formation and binding to fibronectin but increased protease production in vitro, compared with their respective parental strains. Interestingly, exposure to sub-MICs of vancomycin significantly promoted biofilm formation and fibronectin-binding in parental strains but not in sarA mutants. In addition, all sarA mutants became exquisitely susceptible to vancomycin therapy, compared with their respective parental strains, in the infective endocarditis model. CONCLUSIONS: These observations suggest that sarA activation is important in persistent MRSA endovascular infection, potentially in the setting of biofilm formation.
BACKGROUND:Staphylococcus aureus is the most common cause of endovascular infections. The staphylococcal accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant S. aureus (MRSA) persistence in such infections via its influence on biofilm formation. METHODS: Two healthcare-associated MRSA isolates from patients with persistent bacteremia and 2 prototypical community-acquired MRSA strains, as well as their respective isogenic sarA mutants, were studied for in vitro biofilm formation, fibronectin-binding capacity, autolysis, and protease and nuclease activities. These assays were done in the presence or absence of sub-minimum inhibitory concentrations (MICs) of vancomycin. In addition, these strain pairs were compared for intrinsic virulence and responses to vancomycin therapy in experimental infective endocarditis, a prototypical biofilm model. RESULTS: All sarA mutants displayed significantly reduced biofilm formation and binding to fibronectin but increased protease production in vitro, compared with their respective parental strains. Interestingly, exposure to sub-MICs of vancomycin significantly promoted biofilm formation and fibronectin-binding in parental strains but not in sarA mutants. In addition, all sarA mutants became exquisitely susceptible to vancomycin therapy, compared with their respective parental strains, in the infective endocarditis model. CONCLUSIONS: These observations suggest that sarA activation is important in persistent MRSA endovascular infection, potentially in the setting of biofilm formation.
Entities:
Keywords:
MRSA endocarditis; biofilm formation; sarA
Authors: Vance G Fowler; Anita Justice; Catrin Moore; Daniel K Benjamin; Christopher W Woods; Steven Campbell; L Barth Reller; G Ralph Corey; Nicholas P J Day; Sharon J Peacock Journal: Clin Infect Dis Date: 2005-02-04 Impact factor: 9.079
Authors: Willem van Wamel; Yan-Qiong Xiong; Arnold S Bayer; Michael R Yeaman; Cynthia C Nast; Ambrose L Cheung Journal: Microb Pathog Date: 2002-08 Impact factor: 3.738
Authors: Leon Iri Kupferwasser; Michael R Yeaman; Cynthia C Nast; Deborah Kupferwasser; Yan-Qiong Xiong; Marco Palma; Ambrose L Cheung; Arnold S Bayer Journal: J Clin Invest Date: 2003-07 Impact factor: 14.808
Authors: Jon S Blevins; Mohamed O Elasri; Scott D Allmendinger; Karen E Beenken; Robert A Skinner; J Roby Thomas; Mark S Smeltzer Journal: Infect Immun Date: 2003-01 Impact factor: 3.441
Authors: Yan-Qiong Xiong; Arnold S Bayer; Michael R Yeaman; Willem Van Wamel; Adhar C Manna; Ambrose L Cheung Journal: Infect Immun Date: 2004-03 Impact factor: 3.441
Authors: Danielle N Atwood; Karen E Beenken; Allister J Loughran; Daniel G Meeker; Tamara L Lantz; Justin W Graham; Horace J Spencer; Mark S Smeltzer Journal: Infect Immun Date: 2016-03-24 Impact factor: 3.441
Authors: Yan Q Xiong; Angeles Estellés; L Li; W Abdelhady; R Gonzales; Arnold S Bayer; Edgar Tenorio; Anton Leighton; Stefan Ryser; Lawrence M Kauvar Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: R San-Juan; D Pérez-Montarelo; E Viedma; A Lalueza; J Fortún; E Loza; M Pujol; C Ardanuy; I Morales; M de Cueto; E Resino-Foz; M A Morales-Cartagena; M Fernández-Ruiz; A Rico; M P Romero; M Fernández de Mera; F López-Medrano; M Á Orellana; J M Aguado; F Chaves Journal: Eur J Clin Microbiol Infect Dis Date: 2017-05-05 Impact factor: 3.267
Authors: Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong Journal: J Antimicrob Chemother Date: 2015-01-05 Impact factor: 5.790
Authors: Kevin D Mlynek; Logan L Bulock; Carl J Stone; Luke J Curran; Marat R Sadykov; Kenneth W Bayles; Shaun R Brinsmade Journal: J Bacteriol Date: 2020-03-26 Impact factor: 3.490
Authors: Kevin D Mlynek; Mary T Callahan; Anton V Shimkevitch; Jackson T Farmer; Jennifer L Endres; Mélodie Marchand; Kenneth W Bayles; Alexander R Horswill; Jeffrey B Kaplan Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191